Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen

John Christopher G. Gallagher, Warren T. Kable, David Goldgar

Research output: Contribution to journalArticle

173 Citations (Scopus)

Abstract

purpose: To determine the effect of progestin therapy on bone mineral density in postmenopausal women and to compare its effects to those of estrogen. subjects and methods: A prospective, randomized clinical trial was performed in 81 postmenopausal women aged 51.7 ± 4.4 years (mean ± SD). They were assigned to one of four groups: Provera® 20 mg, Premarin® 0.6 mg, Premarin 0.3 mg plus Provera 10 mg, and a placebo. In addition, all women received calcium supplementation, if necessary, to a calcium intake of 1,000 mg/day. We used single- and dual-photon absorpiometry, metacarpal radiogrammetry, and computed axial tomography to measure bone mineral density in the total skeleton, spine, radius, and metacarpal. results: Women receiving placebo lost bone at all sites (p

Original languageEnglish
Pages (from-to)171-178
Number of pages8
JournalAmerican Journal of Medicine
Volume90
Issue number1
DOIs
StatePublished - 1991

Fingerprint

Progestins
Estrogens
Conjugated (USP) Estrogens
Medroxyprogesterone Acetate
Metacarpal Bones
Bone Density
Placebos
Calcium
Therapeutics
Photons
Skeleton
Spine
Randomized Controlled Trials
Tomography
Bone and Bones
Cancellous Bone
Cortical Bone

All Science Journal Classification (ASJC) codes

  • Nursing(all)

Cite this

Effect of progestin therapy on cortical and trabecular bone : comparison with estrogen. / Gallagher, John Christopher G.; Kable, Warren T.; Goldgar, David.

In: American Journal of Medicine, Vol. 90, No. 1, 1991, p. 171-178.

Research output: Contribution to journalArticle

@article{45b3e19c2086474cbf6be92b71c9ac07,
title = "Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen",
abstract = "purpose: To determine the effect of progestin therapy on bone mineral density in postmenopausal women and to compare its effects to those of estrogen. subjects and methods: A prospective, randomized clinical trial was performed in 81 postmenopausal women aged 51.7 ± 4.4 years (mean ± SD). They were assigned to one of four groups: Provera{\circledR} 20 mg, Premarin{\circledR} 0.6 mg, Premarin 0.3 mg plus Provera 10 mg, and a placebo. In addition, all women received calcium supplementation, if necessary, to a calcium intake of 1,000 mg/day. We used single- and dual-photon absorpiometry, metacarpal radiogrammetry, and computed axial tomography to measure bone mineral density in the total skeleton, spine, radius, and metacarpal. results: Women receiving placebo lost bone at all sites (p",
author = "Gallagher, {John Christopher G.} and Kable, {Warren T.} and David Goldgar",
year = "1991",
doi = "10.1016/0002-9343(91)90538-9",
language = "English",
volume = "90",
pages = "171--178",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Effect of progestin therapy on cortical and trabecular bone

T2 - comparison with estrogen

AU - Gallagher, John Christopher G.

AU - Kable, Warren T.

AU - Goldgar, David

PY - 1991

Y1 - 1991

N2 - purpose: To determine the effect of progestin therapy on bone mineral density in postmenopausal women and to compare its effects to those of estrogen. subjects and methods: A prospective, randomized clinical trial was performed in 81 postmenopausal women aged 51.7 ± 4.4 years (mean ± SD). They were assigned to one of four groups: Provera® 20 mg, Premarin® 0.6 mg, Premarin 0.3 mg plus Provera 10 mg, and a placebo. In addition, all women received calcium supplementation, if necessary, to a calcium intake of 1,000 mg/day. We used single- and dual-photon absorpiometry, metacarpal radiogrammetry, and computed axial tomography to measure bone mineral density in the total skeleton, spine, radius, and metacarpal. results: Women receiving placebo lost bone at all sites (p

AB - purpose: To determine the effect of progestin therapy on bone mineral density in postmenopausal women and to compare its effects to those of estrogen. subjects and methods: A prospective, randomized clinical trial was performed in 81 postmenopausal women aged 51.7 ± 4.4 years (mean ± SD). They were assigned to one of four groups: Provera® 20 mg, Premarin® 0.6 mg, Premarin 0.3 mg plus Provera 10 mg, and a placebo. In addition, all women received calcium supplementation, if necessary, to a calcium intake of 1,000 mg/day. We used single- and dual-photon absorpiometry, metacarpal radiogrammetry, and computed axial tomography to measure bone mineral density in the total skeleton, spine, radius, and metacarpal. results: Women receiving placebo lost bone at all sites (p

UR - http://www.scopus.com/inward/record.url?scp=0025905957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025905957&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(91)90538-9

DO - 10.1016/0002-9343(91)90538-9

M3 - Article

C2 - 1847582

AN - SCOPUS:0025905957

VL - 90

SP - 171

EP - 178

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 1

ER -